QIAGEN Launches Fourth-generation QuantiFERON®-TB Gold Plus in the U.S.

Friday, October 6, 2017 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

Novel CD4/CD8 design delivers most comprehensive evaluation of patients' immune response to tuberculosis infection

GERMANTOWN, Maryland and HILDEN, Germany, October 5, 2017 /PRNewswire/ --

QIAGEN

(NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of QuantiFERON®-TB Gold Plus (QFT®-Plus), the fourth generation of its leading blood test for tuberculosis (TB) infection. QFT-Plus kits will be available on October 9, 2017 for diagnostic use following U.S. Food and Drug Administration approval in June.

QFT-Plus advances the science of TB testing with innovative antigens that measure the cell-mediated immune response to tuberculosis infection from both CD4+ and CD8+ T cells - providing a broader assessment of TB infection. CD8+ T cells have been shown to play an important role in Mycobacterium tuberculosis immunity.  

Click here for the full press release

http://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-05-QFT-Plus-Launch-US?sc_lang=en

Contacts: QIAGEN Investor Relations John Gilardi e-mail: [email protected] +49-2103-29-11711 Public Relations Dr. Thomas Theuringer e-mail: [email protected] +49-2103-29-11826

SOURCE QIAGEN



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store